INVA
Innoviva Inc

1,563
Mkt Cap
$2.08B
Volume
186,622.00
52W High
$22.76
52W Low
$16.52
PE Ratio
14.00
INVA Fundamentals
Price
$19.63
Prev Close
$19.51
Open
$19.60
50D MA
$20.42
Beta
0.31
Avg. Volume
941,188.41
EPS (Annual)
$0.3621
P/B
1.44
Rev/Employee
$2.93M
News
all
press releases
Notable Two Hundred Day Moving Average Cross - INVA
In trading on Tuesday, shares of Innoviva Inc (Symbol: INVA) crossed below their 200 day moving average of $19.35, changing hands as low as $19.26 per share. Innoviva Inc shares are currently trading...
Nasdaq News: Markets·8d ago
News Placeholder
More News
News Placeholder
Synergy Asset Management LLC Invests $1.85 Million in Innoviva, Inc. $INVA
Synergy Asset Management LLC acquired a new position in Innoviva, Inc. (NASDAQ:INVA - Free Report) during the 3rd quarter, according to its most recent filing with the SEC. The fund acquired 101,459...
MarketBeat·10d ago
News Placeholder
Innoviva (NASDAQ:INVA) Share Price Crosses Above Two Hundred Day Moving Average - Here's Why
Innoviva (NASDAQ:INVA) Stock Crosses Above Two Hundred Day Moving Average - Here's Why...
MarketBeat·21d ago
News Placeholder
Innoviva, Inc. (NASDAQ:INVA) Receives Consensus Rating of "Moderate Buy" from Analysts
Shares of Innoviva, Inc. (NASDAQ:INVA - Get Free Report) have been given an average rating of "Moderate Buy" by the seven research firms that are presently covering the company, Marketbeat Ratings...
MarketBeat·1mo ago
News Placeholder
FDA Approves Innoviva's NUZOLVENCE, First-in-Class Oral Treatment For Gonorrhea
(RTTNews) - Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (INVA), announced that the U.S. Food and Drug Administration approved NUZOLVENCE (zoliflodacin) for oral suspension, a...
Nasdaq News: Markets·1mo ago
News Placeholder
U.S. FDA Approves NUZOLVENCE (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents
Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (NASDAQ: INVA), today announced that the U.S. Food and Drug Administration (FDA) has approved NUZOLVENCE (zoliflodacin) for oral...
Business Wire·1mo ago
News Placeholder
Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea
Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), today announced the publication of positive results from a pivotal Phase 3 trial evaluating its investigational...
Business Wire·1mo ago
News Placeholder
State Board of Administration of Florida Retirement System Cuts Stake in Innoviva, Inc. $INVA
State Board of Administration of Florida Retirement System decreased its holdings in Innoviva, Inc. (NASDAQ:INVA - Free Report) by 80.4% in the second quarter, according to its most recent 13F filing...
MarketBeat·1mo ago
News Placeholder
Innoviva, Inc. $INVA Shares Purchased by Arrowstreet Capital Limited Partnership
Arrowstreet Capital Limited Partnership raised its stake in Innoviva, Inc. (NASDAQ:INVA - Free Report) by 85.3% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The...
MarketBeat·1mo ago
News Placeholder
Boston Partners Boosts Holdings in Innoviva, Inc. $INVA
Boston Partners lifted its position in shares of Innoviva, Inc. (NASDAQ:INVA - Free Report) by 40.6% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 875,084...
MarketBeat·2mo ago
<
1
2
...
>

Latest INVA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.